Tag: Offers

Categories
Politics

In Milwaukee, Biden Presents Reassurance, and Tries to Keep away from Point out of ‘the Former Man’

In Milwaukee, Biden Offers Reassurance, and Tries to Avoid Mention of ‘the Former Guy’

WASHINGTON – On his first official trip from Washington since taking office, President Biden reassured Americans Tuesday of the availability of coronavirus vaccines and optimism that his $ 1.9 trillion relief bill was an ambitious plan to restore the American economy could.

“Now is the time we should be,” he said at a CNN town hall in Milwaukee, promoting a plan that previously has no Republican support in Congress. “Now is the time to grow up.”

Regarding the coronavirus, he said any American who wanted a vaccine could get one “by the end of July this year,” which sounded more optimistic than last week when he warned that logistical hurdles would most likely mean many Americans would be by the end of Not vaccinated in summer.

“We’ll have over 600 million doses – enough to vaccinate every single American,” he said at an event attended not only by his own supporters, but also by Trump voters and independents.

Mr Biden predicted that “I think that by next Christmas we will be in a very different situation than we are today.”

The town hall’s question-and-answer format gave the president an opportunity to practice what has been his trademark personal politics for decades. For example, when an independent voter asked him how her son with a pre-existing illness could get the vaccine, Mr. Biden said to her, “If you’re ready, I’ll stay after this is over and maybe we can talk a few Minutes and see if I can help you. “

At another point, he comforted an 8-year-old girl whose mother said she was afraid of dying from Covid-19. “You are the safest group of people in the whole world,” he said. “I wouldn’t worry about that baby, I promise you that.”

Mr Biden expressed his condolences for the girl’s missed school days and said that his administration’s goal is still to open most schools to kindergarten students all day within her first 100 days through eighth grade.

The promise appeared to contradict White House press secretary Jen Psaki, who said last week that the government’s once-ambitious reopening target has been scaled back to ensure that more than 50 percent of schools have “at least one class” a day Week ”in the first 100 days. She later added, “We definitely hope to build on it after 100 days.”

But Mr. Biden was reluctant to lower the bar to one day a week in personal school. “That was reported,” said the president. “That’s not true. It was a mistake in communication.”

He also said he expected school to continue throughout the summer to allow students to catch up.

The trip to Milwaukee seemed like a make-up visit of sorts to the city that was slated to host the 2020 National Democratic Convention last summer before the coronavirus pandemic turned plans for face-to-face meetings upside down.

And the situation in a state he won by less than a percentage point in November made sense to a president promoting a plan to help Americans recover from the ravages of the pandemic.

Updated

Apr 16, 2021 at 10:43 am ET

A surge in coronavirus cases made Wisconsin one of the hardest hit states in the fall and early winter, although the numbers have dropped significantly. The state’s unemployment rate of 5.5 percent is also lower than double-digit highs seen in the early days of the pandemic, but is still higher than last winter.

On Tuesday evening, Air Force One landed in a Wisconsin excavated from a blizzard, and when the country’s attention finally turned more to Mr. Biden after the end of the second impeachment trial of his predecessor Donald J. Trump over the weekend.

Mr Biden continued his practice throughout his impeachment and seemed anxious to avoid mentioning his most recent predecessor. At one point he referred to Mr. Trump as “the former man”.

When asked by the moderator, CNN anchor Anderson Cooper, for his thoughts on the impeachment ruling against Mr Trump, Mr Biden said he wanted to move on. “For four years now, everything that’s on the news has been Trump,” he said. “For the next four years, I want to make sure that all news is the American people. I’m tired of talking about Trump. “

At one point, however, he couldn’t resist a veiled dig and told Mr. Cooper that all but one living former president had contacted him by phone to make it clear that it was only Mr. Trump who hadn’t.

When asked by Mr. Cooper how he got used to the presidency, Mr. Biden, who said on inauguration day that it felt like he was “coming home,” seemed humble about the experience.

For one, he was not used to living with a butler who helped him with his coat, as well as with other employees in the White House residence who were there to serve him. “I was brought up so that you weren’t looking for someone to wait for you,” he said. “I am very confident.”

Despite his close relationship with President Barack Obama, Mr Biden said he had never visited the private section of the White House residence before moving in last month. And he said life there is a great contrast to the Vice President’s residence, which has more space and privacy.

“It’s a bit like a gold-plated cage when you can go outside and do things,” he said of life in the White House. “I feel a sense, I have to tell you, a sense of story about it.”

Mr Biden repeatedly apologized when he felt his answers were too complicated or taking too long, and he hoped to lead the country in facing the challenges.

“I literally pray that I have the ability to do what you all deserve for the country,” said Biden.

Ms. Psaki said Tuesday that Mr. Biden hoped “to have a good conversation with people about the way forward and even with people who disagree with it” on the trip. In fact, one of the President’s most vocal critics is Senator Ron Johnson, the state’s Republican Senator, who is vehemently against the Biden bailout plan. But Ms. Psaki said pressure on Mr. Johnson was not the purpose of the trip.

When asked about the divisions in American society, Mr. Biden replied that the country was more unanimous than expected on the need for relief, and found that 69 percent of Americans supported his plan. “The nation is not divided,” he said. “You go out there and look around and talk to people, you have edges on both ends. But it is nowhere near as divided as we imagine. “

Outside the Pabst Theater, where the City Hall was taking place, a group of fast food and other low-wage workers planned a protest to urge Mr. Biden not to give up his promise to raise the minimum wage to $ 15 an hour.

However, the president was asked by several small business owners for his support for a minimum wage of $ 15 an hour, trying to reassure them that the increase would be gradual, as if to show that differences could be overcome. While “no one should work 40 hours a week living in poverty,” said Biden, “it’s perfectly legitimate for small business owners to worry about how this is changing.”

But he highlighted white supremacists as a unique threat to domestic terrorism that needed to be addressed. “I would make sure my Justice Department and Civil Rights Department have a strong focus on these people,” he said. “I would make sure that we actually focus on how to deal with the rise of white supremacy.”

Dan Simmons contributed to coverage from Milwaukee.

Categories
Business

Dip in Unemployment Claims Gives Hope as New Virus Instances Ease

Dip in Unemployment Claims Offers Hope as New Virus Cases Ease

Following a pandemic-induced surge in layoffs due to new restrictions in many states, unemployment claims are falling, aided by a decline in new coronavirus cases.

Initial unemployment benefits fell last week, the Labor Department reported Thursday, and were well below levels in December and early January.

The number of new coronavirus cases is down a third from two weeks ago, prompting states like California and New York to relax restrictions on indoor eating and other activities. This has given workers in the hardest hit industries some respite.

813,000 new state benefit claims were made last week, compared to 850,000 the previous week. Adjusted for seasonal fluctuations, the value for the last week was 793,000, which corresponds to a decrease of 19,000.

There were 335,000 new entitlements to Pandemic Unemployment Assistance, a government-funded program for part-time workers, the self-employed, and others who are normally not eligible for unemployment benefits. That sum, which was not seasonally adjusted, fell from 369,000 the week before.

While claims remain extraordinarily high by historical standards, the improvement has raised hopes that layoffs will continue to slow as vaccinations spread and employers switch from laying off workers to adding workers.

“We’re stuck with this very high level of damage, but activity is picking up,” said Julia Pollak, employment economist at ZipRecruiter, an online job market. In fact, ZipRecruiter’s job postings are at 11.3 million, near the pre-pandemic 11.4 million level.

The improving pandemic situation has eased the burden on restaurants and bars, Ms. Pollak added. With nearly 10 million jobs deficit since the pandemic started and employers still cautious about hiring, the economy is facing major challenges.

Federal Reserve chairman Jerome H. Powell told the New York Business Club on Wednesday that policymakers should continue to focus on restoring employment, “Given the number of people who have lost their jobs and the likelihood that some struggle to find work in the post-pandemic economy. “

He found that employment for workers earning high wages had fallen by only 4 percent, but for the bottom quartile of those in work it was a “staggering 17 percent”.

Updated

Apr. 11, 2021 at 11:13 am ET

Many other signs of weakness remain. The Ministry of Labor reported that employers only created 49,000 jobs in January, underscoring the challenges facing the unemployed.

President Biden cited the poor performance to call for approval of a $ 1.9 trillion pandemic relief package. It would send $ 1,400 to many Americans, aid states and cities, and extend unemployment benefits, which is slated to run out to millions in mid-March.

The House Ways and Means Committee took an initial step on Wednesday when it began developing a measure that would continue emergency benefits through the end of August, increasing the weekly benefit premium from $ 300 to $ 400.

With the prospect of additional relief and a decrease in virus cases, some experts say a strong recovery is possible this year. Oxford Economics is forecasting economic growth of 5.9 percent in 2021, compared to a decline of 3.5 percent in the previous year.

According to economists at ZipRecruiter and another major online job board, Employers, employers are already putting out the welcome mat in certain areas.

Ms. Pollak said employer posts at ZipRecruiter in the past few days have offered hope. “We have seen employers exceed all of our expectations and show a lot of exuberance,” she said. “There are clear differences between different industries.”

In addition to strength in industries that benefit from the stay-at-home trend, such as B. Warehousing and deliveries, the recruitment of engineering, professional and business services has recently shown signs of life.

“Companies are looking to the future and are somewhat optimistic,” said Ms. Pollak.

AnnElizabeth Konkel, an economist at Indeed Hiring Lab, added that demand for pharmacists was up 23 percent year-over-year while openings for drivers were up 18 percent. “Everything is directly related to the pandemic,” said Ms. Konkel.

Nevertheless, there were regional differences. In cities like Washington, Seattle, Boston, and San Francisco, where many people work remotely, there were fewer vacancies in some areas than in places with more people back in the office.

“People don’t come to their local café on their way to work or stop at a store to pick up something when they work at home,” said Ms. Konkel, and that affects attitudes.

Restaurant openings have declined for a year, as have positions in arts and entertainment, hospitality and tourism.

At ZipRecruiter, the energy industry posted more jobs after heavy losses at the beginning of the pandemic. Manufacturing has also seen more openings lately.

“Some of the losers are finally coming back a bit,” said Ms. Pollak. “But so many industries are impossible to resume while the pandemic continues.”

Categories
Business

NFL provides Biden soccer stadiums for Covid vaccination websites

NFL offers Biden football stadiums for Covid vaccination sites

Sofi Stadium, home of the Los Angeles Rams in Inglewood, California.

Keith Birmingham | MediaNews Group | Getty Images

The National Football League announced President Joe Biden that it is making all 32 football stadiums available to the general public as mass coronavirus vaccination sites.

Seven NFL teams are already running vaccinations against Covid-19 in or near their stadiums.

“The NFL and our 32 member clubs are committed to doing our part to ensure that vaccines are as widely available in our communities as possible,” League commissioner Roger Goodell wrote in a letter to Biden on Thursday.

“We can expand our efforts to stadiums more effectively as many of our clubs have been offering their facilities as COVID test centers and polling stations in recent months,” Goodell wrote.

His letter stated that each NFL team would coordinate vaccination efforts at the stadiums with local, state and federal health officials.

It already happened in San Francisco, where the 49ers team and Santa Clara County announced on Friday that Levi’s Stadium would be used as a vaccination site for residents next week.

The team said the stadium will be California’s largest vaccination site with an initial capacity of 5,000 people receiving shots per day and plans to increase that capacity to 15,000 people per day if vaccine supplies increase.

Goodell noted that the NFL will host 7,500 vaccinated health care workers from around the country for Sunday’s Super Bowl game between the Kansas City Chiefs and the Tampa Bay Buccaneers.

The commissioner said workers were invited “out of gratitude for their heroic service and to highlight the importance of vaccinations as our country recovers from the pandemic”.

The NFL referred questions to the White House when contacted by CNBC. The Biden administration had no immediate comment.

The league’s current vaccination sites are hosted by the Arizona Cardinals, Atlanta Falcons, Baltimore Ravens, Carolina Panthers, Houston Texans, Miami Dolphins, and New England Patriots.

A variety of professional baseball stadiums in the US are already offering Covid vaccines to the public.

A temporary mass vaccination site opened on Friday at Yankee Stadium in the Bronx, New York.

Another location in the Mets house in Citi Field, Queens, should have recordings in late January. However, this opening was postponed as the city lacked sufficient vaccines.

Los Angeles turned Dodger Stadium into a mass vaccination site in January after serving as a mass covid testing site for eight months.

– CNBC’s Noah Higgins-Dunn contributed to this report.

Categories
Health

Johnson & Johnson’s Vaccine Provides Sturdy Safety however Fuels Concern About Variants

Johnson & Johnson’s Vaccine Offers Strong Protection but Fuels Concern About Variants

[Live updates: follow our coverage of the coronavirus]

Johnson & Johnson announced on Friday that its one-dose coronavirus vaccine provided strong protection against Covid-19, potentially offering the United States a third powerful tool in a desperate race against a worldwide rise in virus mutations.

But the results came with a significant cautionary note: The vaccine’s efficacy rate dropped from 72 percent in the United States to 57 percent in South Africa, where a highly contagious variant is driving most cases. Studies suggest that this variant also blunts the effectiveness of Covid vaccines made by Pfizer-BioNTech, Moderna and Novavax. The variant has spread to at least 31 countries, including the United States, where two cases were documented this week.

Johnson & Johnson said that it planned to apply for emergency authorization of the vaccine from the Food and Drug Administration as soon as next week, putting it on track to receive clearance later in February.

“This is the pandemic vaccine that can make a difference with a single dose,” said Dr. Paul Stoffels, the chief scientific officer of Johnson & Johnson.

The Johnson & Johnson vaccine was 85 percent effective in preventing severe disease, regardless of what variant caused it, the company said. While less effective than the Moderna and Pfizer vaccines, Johnson & Johnson’s is still considered a strong vaccine by scientists. Annual flu vaccines, for example, are typically 40 to 60 percent effective.

The company’s announcement comes as the Biden administration is pushing to immunize Americans faster even with a tight vaccine supply. White House officials have been counting on Johnson & Johnson’s vaccine to ease the shortfall. But the company may only have about seven million doses ready when the F.D.A. decides whether to authorize it, according to federal health officials familiar with its production, and about 30 million doses by early April.

The variant from South Africa, known as B.1.351, could make things even worse for the vaccine push. Given the speed at which the variant swept through that country, it is conceivable that by April it could make up a large fraction of infections in the United States.

The fact that four vaccines backed by the federal government seem to be less effective against the B.1.351 variant has unsettled federal officials and vaccine experts alike. Facing this uncertainty, many researchers said it was imperative to get as many people vaccinated as possible — quickly. Lowering the rate of infection could thwart the contagious variants while they are still rare, and prevent other viruses from gaining new mutations that could cause more trouble.

“If ever there was reason to vaccinate as many people as expeditiously as we possibly can with the vaccine that we have right now, now is the time,” Dr. Anthony S. Fauci, the government’s top infectious disease expert, said in an interview. “Because the less people that get infected, the less chance you’re going to give this particular mutant a chance to become dominant.”

As the United States scrambles to get enough vaccines, the country is turning into something of an evolutionary experiment. The B.1.351 variant is one of several that have arrived in the country or originated here, all with the ability to spread faster than other variants.

“The pandemic is a lot more complicated now than it was a couple months ago,” said Dr. Dan Barouch, a virologist at Beth Israel Medical Center in Boston.

Vaughan Cooper, an evolutionary biologist at the University of Pittsburgh, said that all the new variants were likely evolving quietly for months before bursting on the scene. “I think we’re going to see many stories like this,” he said.

Federal regulators are also still waiting on data from Johnson & Johnson’s new manufacturing facility in Baltimore that prove it can mass-produce the vaccine. The company is counting on that factory to help reach its contractual pledge to the federal government of 100 million doses by the end of June.

If Johnson & Johnson can deliver vaccines quickly enough to the United States, it might be able to help drive down cases before variants make things worse. Since the vaccine requires only a single shot — unlike the Moderna and Pfizer-BioNTech vaccines, which require two — that delivery would translate into full coverage for 100 million people.

Johnson & Johnson’s vaccine has another advantage that might help speed up the rollout. It can stay viable in a refrigerator for three months, while the two authorized vaccines have to be kept frozen. That gives the company an edge not just in reaching more isolated parts of the United States, but in getting the vaccine to remote areas of the world that could otherwise seed more aggressive mutants.

“I hope this vaccine gets approved as soon as possible to reduce disease burden around the world,” said Akiko Iwasaki, immunologist at Yale University. She pointed out that the shot greatly reduced the number of severe Covid cases, even those caused by the variant. “This is a really great result.”

Still, Johnson & Johnson and other vaccine makers must prepare for the B.1.351 variant or another one surging to dominance and demanding new vaccines. “You’ve got to be nimble enough to be able to adapt by upgrading our vaccines that match the dominant strain,” Dr. Fauci said.

Exactly when to make that switch will be a difficult decision, because the viruses are spreading unpredictably, and manufacturing new doses will be a huge undertaking.

“The implications of that are big. You would not take that choice lightly,” said John D. Grabenstein, an epidemiologist with the Immunization Action Coalition, a nonprofit organization that disseminates information about vaccines. “It’s not doomsday. It’s just that we are going to need a bigger boat.”

Johnson & Johnson’s announcement came one day after Novavax said an early analysis of its 15,000-person trial in Britain had revealed that the two-dose vaccine had an efficacy rate of nearly 90 percent there. But in a small trial in South Africa, the efficacy rate dropped to just under 50 percent.

Johnson & Johnson presented only a summary of findings of its clinical trial. The vaccine was 85 percent effective in preventing severe disease in all three regions where the trial was run: the United States, Latin America and South Africa. After 28 days, none of the vaccinated participants who developed Covid-19 had to be hospitalized.

The company reported that the vaccine’s protective effect seems to increase with time. But without long-term data on immunity, scientists and regulators do not yet know whether the vaccine’s efficacy peaks at some point before dropping.

Covid-19 Vaccines ›

Answers to Your Vaccine Questions

Am I eligible for the Covid vaccine in my state?

Currently more than 150 million people — almost half the population — are eligible to be vaccinated. But each state makes the final decision about who goes first. The nation’s 21 million health care workers and three million residents of long-term care facilities were the first to qualify. In mid-January, federal officials urged all states to open up eligibility to everyone 65 and older and to adults of any age with medical conditions that put them at high risk of becoming seriously ill or dying from Covid-19. Adults in the general population are at the back of the line. If federal and state health officials can clear up bottlenecks in vaccine distribution, everyone 16 and older will become eligible as early as this spring or early summer. The vaccine hasn’t been approved in children, although studies are underway. It may be months before a vaccine is available for anyone under the age of 16. Go to your state health website for up-to-date information on vaccination policies in your area

Is the vaccine free?

You should not have to pay anything out of pocket to get the vaccine, although you will be asked for insurance information. If you don’t have insurance, you should still be given the vaccine at no charge. Congress passed legislation this spring that bars insurers from applying any cost sharing, such as a co-payment or deductible. It layered on additional protections barring pharmacies, doctors and hospitals from billing patients, including those who are uninsured. Even so, health experts do worry that patients might stumble into loopholes that leave them vulnerable to surprise bills. This could happen to those who are charged a doctor visit fee along with their vaccine, or Americans who have certain types of health coverage that do not fall under the new rules. If you get your vaccine from a doctor’s office or urgent care clinic, talk to them about potential hidden charges. To be sure you won’t get a surprise bill, the best bet is to get your vaccine at a health department vaccination site or a local pharmacy once the shots become more widely available.

Can I choose which vaccine I get?How long will the vaccine last? Will I need another one next year?

That is to be determined. It’s possible that Covid-19 vaccinations will become an annual event, just like the flu shot. Or it may be that the benefits of the vaccine last longer than a year. We have to wait to see how durable the protection from the vaccines is. To determine this, researchers are going to be tracking vaccinated people to look for “breakthrough cases” — those people who get sick with Covid-19 despite vaccination. That is a sign of weakening protection and will give researchers clues about how long the vaccine lasts. They will also be monitoring levels of antibodies and T cells in the blood of vaccinated people to determine whether and when a booster shot might be needed. It’s conceivable that people may need boosters every few months, once a year or only every few years. It’s just a matter of waiting for the data.

Will my employer require vaccinations?Where can I find out more?

Dr. Stoffels said the company was still waiting for more data on whether the vaccine can protect against asymptomatic infection.

The company is preparing a lengthy briefing document it will submit to the F.D.A. in its application for authorization. The agency’s scientists will review the raw data from the trial and present their own analysis.

Unlike the messenger RNA vaccines made by Pfizer-BioNTech and Moderna, Johnson & Johnson uses an adenovirus, which normally causes the common cold. While adenovirus-based vaccines have been investigated for some three decades, they have yet to be licensed for use in the United States.

Johnson & Johnson’s Ebola vaccine became the first approved adenovirus-based vaccine for any disease when European regulators gave it the green light last July. Astra-Zeneca and the University of Oxford used a different adenovirus for their coronavirus vaccine, which is now authorized in Britain and other countries. Russian scientists created their Sputnik V vaccine from adenoviruses as well.

Johnson & Johnson received $456 million from Operation Warp Speed to support its research. In July, the government agreed to purchase 100 million doses for $1 billion if it proved safe and effective.

That same month, the company moved into clinical trials, which found that a single shot produced a strong immune response, consistent with experiments done on monkeys. Johnson & Johnson began the final “Phase 3” trial in September, again using a single dose. It recruited volunteers in the United States, South Africa and Latin America.

Half of the volunteers received the vaccine, and half received a placebo. The company then had to wait. Only when enough people in the trial got Covid-19 would an independent board of advisers look at the results to see how many sick volunteers were vaccinated — a process known as unblinding.

Late last year, surges of coronavirus infections accelerated the trial toward unblinding. In December, Johnson & Johnson decided it would not need to recruit 60,000 volunteers as it originally planned. It capped the trial at 45,000.

Like other vaccine developers, Johnson & Johnson was required by the F.D.A. to also record information about adverse events experienced by the volunteers for the first few months after vaccination.

Dr. Barouch, who led the team that designed the vaccine and tested it on animals last year, had to wait for months for the unblinding. “I’m thinking a lot about it,” he said in a Jan. 11 interview. “But, no, I don’t have champagne ready to go.”

After he learned the results, Dr. Barouch said he was delighted. “I think this vaccine will have a public health benefit throughout the world,” he said.

Johnson & Johnson is also moving forward with other trials of the vaccine to see how it can be improved. In December it began a trial with two doses. Dr. Fauci was optimistic that people who get a so-called prime boost may enjoy even more protection.

“If they get a prime boost, it’s entirely conceivable that they can get up to 90-plus percent,” he said.

In addition, Dr. Stoffels said that Johnson & Johnson was tailoring a version of its vaccine with a protein patterned after the B.1.351 variant. It could potentially deploy it in countries where that version of the virus was a threat.

“Pretty much all vaccine developers now are having that conversation,” said Dr. Peter J. Hotez, a vaccine expert with the Baylor School of Medicine and the creator of a different coronavirus vaccine.

Categories
Entertainment

Stimulus Provides $15 Billion in Reduction for Struggling Arts Venues

Stimulus Offers $15 Billion in Relief for Struggling Arts Venues

For music venue owners, theater producers and cultural institutions who have suffered without a business from the pandemic, the coronavirus aid package agreed by Congress leaders this week finally offers the prospect of help: it includes $ 15 billion to help them cope helping a crisis that has shut theaters and silenced halls.

The money, part of a $ 900 billion coronavirus aid package, is set to help the cultural sector – from pub rock clubs to Broadway theaters and museums – survive. Many small business owners cited it as their last hope of staying in business after nearly a year of drought.

“This is what our industry needs to get through,” said Dayna Frank, owner of First Avenue, a famous Minneapolis music club. She is also the chairman of the board of the National Independent Venue Association, which was formed in April and which has aggressively engaged Congress to facilitate its more than 3,000 members.

When the news of the deal broke on Sunday night, a collective sigh of relief rebounded through group text messages and social media posts. “Last night was the first time I smiled in nine months,” said Ms. Frank.

Broadway theaters, which have been closed since March, welcomed the aid package.

“We are grateful for this bipartisan agreement, which is immediate relief and a lifeline for our industry for the future,” said Charlotte St. Martin, president of the Broadway League, the trade organization for producers and theater owners, in a statement.

Nataki Garrett, the artistic director of the Oregon Shakespeare Festival, said helping nonprofit theaters is vital. “Our situation was critical and dire,” she said.

However, those in charge of some large nonprofit cultural organizations feared that the way the bill is structured, giving precedence to organizations that have lost a very high percentage of their revenue before considering the rest, are pushing them to the background for scholarships As this is usually the case, you could receive a significant portion of the income through donations.

With the bill scheduled for approval by both houses of Congress on Monday evening, art groups across the country cautiously celebrated while studying the fine print to see what kind of help they might qualify for. Most doubt that the entertainment industry will not be able to get back into action until well into next year at the earliest.

The bill allows independent entertainment companies such as music venues and cinemas, as well as other cultural institutions, to apply for grants from the Small Business Administration to support six-month payments to employees, as well as costs such as rent, supplies, and maintenance. Applicants must have lost at least 25 percent of their sales to qualify, and those who have lost more than 90 percent can apply first within the first two weeks of the law going into effect.

Updated

Apr. 21, 2020, 4:40 pm ET

The grants are capped at $ 10 million.

The core of these provisions was proposed in the Senate in July by Amy Klobuchar, Democrat of Minnesota and John Cornyn, Republican of Texas. As the relief efforts in Washington wore off for months, venues and institutions began to lose. According to the independent venue association, at least 300 music spots have been closed since the beginning of the pandemic.

Senator Klobuchar certified that the event groups were tirelessly campaigning to convince members of the Congress of their economic and cultural value to local communities.

“It was the basic efforts of musicians, theaters and fans across the country,” said Ms. Klobuchar in an interview on Monday. “And it was the fact that the coalition stuck together. You didn’t fight. “

The pandemic forced small music venues and nonprofit theaters – usually strangers to Washington – to learn the art of lobbying. The owners talked about the elbow grease they put into building their business, the added value to local communities through tourism and hospitality, and the historical role arts organizations have played in revitalizing the tainted corridors of urban America.

The idea that cultural groups are suffering in every corner of the country helped this part of the overall relief package gain broad support from both parties.

In addition to theaters and museums, talent agents and managers can also apply for relief under the law. The bill would restrict listed companies and other large companies.

“I wanted to make sure that the ticketmasters of the world didn’t benefit from it,” said Ms. Klobuchar.

Chuck Schumer, the Democratic leader in the Senate, was an aggressive advocate of cultural relief – he wore a mask that read “Save Our Stages” during the last Capitol Hill negotiations last week – with a special focus on groups in New, of course York, including Broadway theaters.

“It wasn’t just Broadway,” said Mr Schumer in an interview. “Rather, it was the independent venues that were the lifeblood of New York. Young people come to New York, and that’s one of the reasons they come – to cities in general, not just New York. “

“The non-profit and artistic world is very important to the economy of cities,” he added. “People forget that.”

For some of the help-out mom and pop operators, the process has been a do-or-die necessity, albeit a confusing one.

“We used to call managers and agents to book talent,” said Chris Bauman of Zenith Music Group, which operates a handful of Chicago venues. “Now we’ve been thrown into this crazy world of politics. Eighty hours a week of zooms with mayors, senators, and congressmen. “

“It shows that there is a way to do this,” added Bauman, fighting back tears. “Not to be left behind.”

Sarah Bahr contributed to the reporting.

Categories
Business

Pfizer’s Vaccine Gives Sturdy Safety After First Dose

Pfizer’s Vaccine Offers Strong Protection After First Dose

WASHINGTON – The coronavirus vaccine, manufactured by Pfizer and BioNTech, offers strong protection against Covid-19 within about 10 days of the first dose. This emerges from documents released Tuesday by the Food and Drug Administration ahead of a meeting of their vaccine advisory group.

The result is one of several significant new results in the newsletters, which includes more than 100 pages of data analysis from the Agency and Pfizer. Last month Pfizer and BioNTech announced that their two-dose vaccine had a 95 percent effectiveness rate after two doses three weeks apart. The new analyzes show that protection starts much earlier.

In addition, the vaccine worked well regardless of the race, weight, or age of a volunteer. While no serious adverse events from the vaccine were identified in the study, many participants experienced pain, fever, and other side effects.

“This is what an A + certificate looks like for a vaccine,” said Akiko Iwasaki, an immunologist at Yale University.

On Thursday, the FDA’s Vaccine Advisory Panel will discuss these materials prior to a vote on whether to recommend approval of the vaccine by Pfizer and BioNTech.

Pfizer and BioNTech started a large-scale clinical trial in July that recruited 44,000 people in the US, Brazil and Argentina. Half of the volunteers received the vaccine and half the placebo.

New coronavirus cases in the vaccinated group of volunteers quickly subsided about 10 days after the first dose, according to a graphic in the educational materials. The number of cases increased steadily in the placebo group.

The vaccine’s swift action could benefit not only the people who receive it, but also the strained hospitals in the country, limiting the flow of new patients to intensive care units.

Despite the early protection provided by the first dose, it is unclear how long this protection would last on its own, which underscores the importance of the second dose. Previous studies have shown that the second dose of the Pfizer BioNTech vaccine gives the immune system a significant long-term boost that is seen with many other vaccines.

The effectiveness of the vaccine after the first dose, according to Dr. William C. Gruber, senior vice president of Pfizer Vaccine Clinical Research and Development, at about 52 percent. After the second dose, this value increases to about 95 percent. “Two doses of the vaccine offer maximum protection,” he said.

Many experts have raised concerns that the coronavirus vaccines might protect some people better than others. However, the results in the educational materials indicate no such problem. The vaccine has a high rate of effectiveness in both men and women, and similar rates in whites, blacks, and Latinos. It also worked well on obese people who are at higher risk of developing Covid-19.

Some vaccines for other diseases produce a weak immune response in older adults. However, Pfizer and BioNTech found that people over 65 received about as much protection from the coronavirus vaccine as younger people.

“I’ve never seen anything like it,” said Dr. Gregory Poland, a vaccine researcher at the Mayo Clinic, on the vaccine’s robust response in the overweight and elderly.

Even if the vaccine is approved by the FDA, the study will continue. In the briefing documents, the companies said they would encourage people to stay in the study for as long as possible without knowing whether they received the vaccine or the placebo, so the researchers can continue to gather information on whether the vaccine is safe and effective.

The road to a coronavirus vaccine

Interesting facts about vaccines

Confused by all of the technical terms used to describe how vaccines work and study? Let us help:

    • Adverse event: A health problem that occurs in volunteers in a clinical trial with a vaccine or drug. An adverse event is not always caused by the treatment tested in the study.
    • Antibody: A protein produced by the immune system that can attach to a pathogen such as the coronavirus and prevent it from infecting cells.
    • Approval, Licensing, and Approval for Emergency Use: Medicines, vaccines and medical devices cannot be sold in the US for no profit approval by the Food and Drug Administration, also known as Licensing. After a company submits the results of clinical studies to the FDA for review, the agency decides whether the product is safe and effective. This process usually takes many months. If the country faces an emergency – like a pandemic – a company can file an application instead Emergency approvalthat can be granted much faster.
    • Background rate: How often does the general population experience a health problem called an Adverse Event? To determine whether a vaccine or drug is safe, researchers compare the rate of adverse events in one study to the background rate.
    • Effectiveness: The benefit of a vaccine compared to a placebo, measured in a clinical trial. For example, to test a coronavirus vaccine, the researchers compare how many people in the vaccinated group and the placebo group are receiving Covid-19. In contrast, effectiveness is the benefit that a vaccine or drug offers in the real world. A vaccine’s effectiveness can be found to be less or more effective than its effectiveness.
    • Phases 1, 2 and 3 studies: Clinical trials typically take place in three phases. Phase 1 studies typically involve a few dozen people to determine whether a vaccine or drug is safe. In Phase 2 trials that involve hundreds of people, researchers can try different doses and take more measurements of the vaccine’s effects on the immune system. Phase 3 trials, involving thousands or tens of thousands of volunteers, determine the safety and effectiveness of the vaccine or medicine by waiting to see how many people are protected from the disease it is intended to be used against.
    • Placebo: A substance with no therapeutic effect that is widely used in clinical trials. For example, to see if a vaccine can prevent Covid-19, researchers can inject the vaccine into half of their volunteers while the other half are given a placebo with salt water. You can then compare how many people are infected in each group.
    • Post-market surveillance: The surveillance that occurs after a vaccine or drug has been approved and regularly prescribed by doctors. This monitoring usually confirms that the treatment is safe. Rarely, side effects are noted in certain groups of people that were overlooked during clinical trials.
    • Preclinical Research: Studies that take place prior to the start of a clinical trial typically include experiments that test a treatment on cells or animals.
    • Viral vector vaccines: A type of vaccine that uses a harmless virus to deliver immune-stimulating ingredients into the human body. Viral vectors are used in several experimental Covid-19 vaccines, including those developed by AstraZeneca and Johnson & Johnson. Both companies use a cold virus called adenovirus as a vector. The adenovirus carries coronavirus genes.
    • Test protocol: A series of procedures that must be performed during a clinical trial.

The educational materials also provide a deeper look into the safety of the vaccine. In any large clinical trial, some people who receive vaccines have health conditions unrelated to the vaccine itself. Comparing their symptom rates with those of the placebo group, as well as background rates in a population, may indicate symptoms that a vaccine may actually cause.

The FDA concluded that there were no “significant imbalances” between the two groups in serious health complications known as adverse events. The agency found that four people in the vaccinated group had a form of facial paralysis called Bell’s palsy, with no cases in the placebo group. The difference between the two groups was not significant and the rate in the vaccinated group was not significantly higher than in the general population.

The new Pfizer analysis found that many volunteers who received the vaccine felt sick in the hours after the second dose, suggesting that many people may need to request a day off or be willing to rest until symptoms appear ease up. Among the 16 to 55 year olds, more than half developed fatigue and more than half also reported headaches. Slightly more than a third experienced chills and 37 percent had muscle pain. About half of those over 55 felt tired, a third had a headache, and about a quarter felt chills, while 29 percent had muscle pain.

“Taking a day off after the second dose is a good thing to anticipate,” said Dr. Iwasaki.

On Monday, Kristen Choi, a psychiatric nurse and health care researcher at the University of California at Los Angeles, released a firsthand report on the symptoms she experienced as a participant in the Pfizer BioNTech study, including chills, nausea and headaches and fever.

“Doctors need to be prepared to discuss with patients why they should trust the vaccine and that its adverse effects could be very similar to Covid-19,” wrote Dr. Choi in JAMA Internal Medicine. She advised doctors to tell patients that these uncomfortable symptoms “are a sign that the vaccine is working despite the unfortunate similarities with the symptoms of the disease”.